TOPIC
RESMED News & Analysis
Stocks
Solid global sales and margin expansion are highlights from latest quarter.
Shane Ponraj | 26 October 2024
Stocks
With data showing the continued rise of SMSFs, we explore the top stock picks of individual investors
Simonelle Mody | 16 October 2024
Stocks
Shares are up 25% year to date but still screen as undervalued.
Shane Ponraj | 04 August 2024
Video
Morningstar analyst Shane Ponraj discusses the latest clinical trial results from Eli Lilly.
Joseph Taylor | 28 June 2024
Stocks
Phil Fisher achieved remarkable stock market returns by holding high quality growth companies for long periods of time. Here's how he found them.
Joseph Taylor | 14 June 2024
Stocks
Strong device sales and rebound in margin.
Shane Ponraj | 29 April 2024
Stocks
Despite advancing from its October low, the undervalued stock of this narrow-moat company may have more room to run.
Shane Ponraj | 14 March 2024
Stocks
Shares rose after strong earnings report but remain materially undervalued.
Shane Ponraj | 29 January 2024
Stocks
Stock markets are highly efficient in the long run yet share prices can fluctuate wildly near term. The art of investing is buying quality stocks...
James Gruber | 23 November 2023
Stocks
Analysts predict margin expansion on a materially undervalued stock.
Shani Jayamanne | 30 October 2023
of 3
Viewing 1 to 10 of 24